secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001140361-25-019326
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma reports positive Phase 1 data for RP-A601 in PKP2-ACM
-------------------------------------------------------------------

- RP-A601 well-tolerated; no dose-limiting toxicities in 3 patients with up to 12 months follow-up.
- PKP2 protein expression increased ~110% and ~398% from baseline in 2 patients with low expression.
- Improved RV function, KCCQ-12 scores (34-41 points), and NYHA class (II to I) in patients.
- PVCs reduced 9-63%; NSVT episodes eliminated in one patient. No further dose escalation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125019326/0001140361-25-019326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125019326/ef20049151_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-019326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer